Compare DTCX & INMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DTCX | INMB |
|---|---|---|
| Founded | N/A | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 80.7M | 64.7M |
| IPO Year | 2021 | 2018 |
| Metric | DTCX | INMB |
|---|---|---|
| Price | $2.02 | $2.46 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $5.40 |
| AVG Volume (30 Days) | 288.0K | ★ 317.9K |
| Earning Date | 04-13-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 8.00 | ★ 11.85 |
| EPS | N/A | ★ N/A |
| Revenue | $2,446.00 | ★ $50,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 257.14 |
| 52 Week Low | $1.51 | $1.09 |
| 52 Week High | $3.80 | $2.60 |
| Indicator | DTCX | INMB |
|---|---|---|
| Relative Strength Index (RSI) | 46.35 | 66.18 |
| Support Level | $1.74 | $1.16 |
| Resistance Level | $2.31 | $2.50 |
| Average True Range (ATR) | 0.29 | 0.13 |
| MACD | -0.06 | 0.00 |
| Stochastic Oscillator | 14.07 | 76.92 |
Datacentrex Inc is a digital infrastructure and capital deployment company that owns and operates Scrypt compute assets and evaluates strategic transactions across asset-backed operating businesses. Its current operating platform is centered on owned and operated Scrypt-based proof-of-work compute deployed through third-party colocation facilities. Datacentrex monetizes this compute through hashrate marketplace mechanisms and manages a treasury of digital assets and cash in a manner intended to preserve capital and support opportunistic, accretive deployment. The company's operations are principally operated remotely at various data centers throughout the United States.
INmune Bio Inc is a clinical stage biotechnology pharmaceutical company focused on developing and commercializing its product candidates to treat diseases where inflammation and immunology cause a dysfunctional immune system contributing to disease. The company's pipeline products include INKmune, XPro1595, and others. It has three product platforms; The CORDStrom product platform, The DN-TNF product platform, and The Natural Killer Cell Priming Platform.